Chocolate's Future Could Hinge on Success of Growing Cocoa Not Just in The Tropics, But in The Lab

FILE PHOTO: A worker cools chocolate during a manufacturing process in  Belgium, May 15, 2024. REUTERS/Yves Herman/File Photo
FILE PHOTO: A worker cools chocolate during a manufacturing process in Belgium, May 15, 2024. REUTERS/Yves Herman/File Photo
TT

Chocolate's Future Could Hinge on Success of Growing Cocoa Not Just in The Tropics, But in The Lab

FILE PHOTO: A worker cools chocolate during a manufacturing process in  Belgium, May 15, 2024. REUTERS/Yves Herman/File Photo
FILE PHOTO: A worker cools chocolate during a manufacturing process in Belgium, May 15, 2024. REUTERS/Yves Herman/File Photo

Climate change is stressing rainforests where the highly sensitive cocoa bean grows, but chocolate lovers need not despair, say companies that are researching other ways to grow cocoa or develop cocoa substitutes.
Scientists and entrepreneurs are working on ways to make more cocoa that stretch well beyond the tropics, from Northern California to Israel, The Associated Press said.
California Cultured, a plant cell culture company, is growing cocoa from cell cultures at a facility in West Sacramento, California, with plans to start selling its products next year. It puts cocoa bean cells in a vat with sugar water so they reproduce quickly and reach maturity in a week rather than the six to eight months a traditional harvest takes, said Alan Perlstein, the company's chief executive. The process also no longer requires as much water or arduous labor.
“We see just the demand of chocolate monstrously outstripping what is going to be available,” Perlstein said. “There's really no other way that we see that the world could significantly increase the supply of cocoa or still keep it at affordable levels without extensive either environmental degradation or some significant other cost.”
Cocoa trees grow about 20 degrees north and south of the equator in regions with warm weather and abundant rain, including West Africa and South America. Climate change is expected to dry out the land under the additional heat. So scientists, entrepreneurs and chocolate-lovers are coming up with ways to grow cocoa and make the crop more resilient and more resistant to pests — as well as craft chocolatey-tasting cocoa alternatives to meet demand.
The market for chocolate is massive with sales in the United States surpassing $25 billion in 2023, according to the National Confectioners Association. Many entrepreneurs are betting on demand growing faster than the supply of cocoa. Companies are looking at either bolstering the supply with cell-based cocoa or offering alternatives made from products ranging from oats to carob that are roasted and flavored to produce a chocolatey taste for chips or filling.
The price of cocoa soared earlier this year because of demand and troubles with the crop in West Africa due to plant disease and changes in weather. The region produces the bulk of the world’s cocoa.
“All of this contributes to a potential instability in supply, so it is attractive to these lab-grown or cocoa substitute companies to think of ways to replace that ingredient that we know of as chocolatey-flavored,” said Carla D. Martin, executive director of the Fine Cacao and Chocolate Institute and a lecturer in African and African American Studies at Harvard University.
The innovation is largely driven by demand for chocolate in the US and Europe, Martin said. While three-quarters of the world's cocoa is grown in West and Central Africa, only 4% is consumed there, she said.
The push to produce cocoa indoors in the US comes after other products, such as chicken meat, have already been grown in labs. It also comes as supermarket shelves fill with evolving snack options — something that developers of cocoa alternatives say shows people are ready to try what looks and tastes like a chocolate chip cookie even if the chip contains a cocoa substitute.
They said they also are hoping to tap into rising consciousness among consumers about where their food comes from and what it takes to grow it, particularly the use of child labor in the cocoa industry.
Planet A Foods in Planegg, Germany, contends the taste of mass market chocolate is derived largely from the fermentation and roasting in making it, not the cocoa bean itself. The company's founders tested out ingredients ranging from olives to seaweed and settled on a mix of oats and sunflower seeds as the best tasting chocolate alternative, said Jessica Karch, a company spokesperson. They called it “ChoViva” and it can be subbed into baked goods, she said.
“The idea is not to replace the high quality, 80% dark chocolate, but really to have a lot of different products in the mass market,” Karch said.
Yet while some are seeking to create alternative cocoa sources and substitutes, others are trying to bolster the supply of cocoa where it naturally grows. Mars, which makes M&Ms and Snickers, has a research facility at University of California, Davis aimed at making cocoa plants more resilient, said Joanna Hwu, the company's senior director of cocoa plant science. The facility hosts a living collection of cocoa trees so scientists can study what makes them disease-resistant to help farmers in producing countries and ensure a stable supply of beans.
“We see it as an opportunity, and our responsibility,” Hwu said.
In Israel, efforts to expand the supply of cocoa are also underway. Celleste Bio is taking cocoa bean cells and growing them indoors to produce cocoa powder and cocoa butter, said co-founder Hanne Volpin. In a few years, the company expects to be able to produce cocoa regardless of the impact of climate change and disease — an effort that has drawn interest from Mondelez, the maker of Cadbury chocolate.
“We only have a small field, but eventually, we will have a farm of bioreactors,” Volpin said.
That's similar to the effort under way at California Cultured, which plans to seek permission from the US Food and Drug Administration to call its product chocolate, because, according to Perlstein, that's what it is.
It might wind up being called brewery chocolate, or local chocolate, but chocolate no less, he said, because it's genetically identical though not harvested from a tree.
“We basically see that we're growing cocoa — just in a different way,” Perlstein said.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”